chronic kidney disease therapeutic program (AstraZeneca/BenevolentAI)

N/A

Report date: 2025/01/26 16:26:52
NME

Base Information

Drug Namechronic kidney disease therapeutic program (AstraZeneca/BenevolentAI)
Drug Alias Namechronic kidney disease therapy (BenevolentAI/AstraZeneca)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsKidney Failure, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBenevolentAI Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBenevolentAI LtdAstrazeneca Plc
Inactive CompaniesN/A
Active IndicationsKidney Failure, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A